New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:45 EDTTEVA, TEVA, HSP, HSP, VRX, VRX, MYL, MYL, ENDP, ENDP, PRGO, PRGO, ACT, ACT, JAZZ, JAZZ, MNK, MNK, SLXP, SLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Analyst will discuss his initiation of coverage of Specialty Pharmaceuticals on a conference call on July 23 at 11 am. Tickers to be discussed include TEVA, MNK, JAZZ, ACT, PRGO, ENDP, MYL, VRX, HSP, SLXP.
News For TEVA;MNK;JAZZ;ACT;PRGO;ENDP;MYL;VRX;HSP;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
09:33 EDTVRXValeant made Zoetis approach as courtesy to Ackman, CNBC reports
Subscribe for More Information
09:33 EDTVRXValeant not going to pursue Zoetis acquisition, CNBC's Faber reports
06:06 EDTVRXZoetis downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
06:02 EDTVRXJPMorgan assumes Valeant pays $60/share for Zoetis
JPMorgan analyst Chris Schott believes Zoetis (ZTS) would bring "an attractive, durable, cash-pay business" to Valeant's portfolio should a merger occur. The Wall Street Journal last night reported that Valeant has approached Zoetis regarding a potential takeover. Schott sees the deal being minimally accretive to near-term earnings, and assumes Valeant pays $60 per share for Zoetis, or a 20% premium to Wednesday's closing price. The analyst thinks any offer would include a substantial equity component given Valeant's levered balance sheet following the Salix acquisition. Schott keeps an Overweight rating on Valeant and a Neutral rating on Zoetis.
June 25, 2015
16:13 EDTVRXValeant made preliminary takeover approach to Zoetis, WSJ reports
Valeant Pharmaceuticals (VRX) made a preliminary approach regarding a potential deal to buy Zoetis (ZTS), said The Wall Street Journal, citing people familiar with the matter. The report said it was not clear if Zoetis is open to a sale or what was the company’s reaction to the approach. Zoetis share spiked more than 11% into the close following the report and are up another 1% to $55.95 in after hours trading. Reference Link
15:58 EDTVRXZoetis jumps 11%, halted for circuit breaker after report of Valeant approach
Subscribe for More Information
15:57 EDTVRXValeant made preliminary takeover approach to Zoetis, DJ reports
Subscribe for More Information
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVA, MYL, PRGOEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
07:06 EDTHSPHospira: FDA deems India facility 'acceptable' for manufacturing
Hospira said in a regulatory filing that on June 23, Hospira Healthcare India Private Limited, a subsidiary of Hospira, received official notification from the U.S. FDA that the inspection of the Visakhapatnam, India facility was deemed acceptable for the manufacture of finished dosage drugs. As a result of this action, the company may receive U.S. product approvals from this facility in the future. As was previously reported, the FDA conducted a pre-approval inspection of the Vizag facility from February 16 to February 25, which resulted in the issuance of a Form 483 containing 14 observations. Hospira responded to the Form 483 on March 18, and submitted additional support documentation on May 29. The inspection was found to be acceptable following the FDA’s review of the company’s responses and support documentation. The company has begun limited commercial production at the facility.
June 23, 2015
14:16 EDTTEVA, MYL, PRGOBMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
11:12 EDTMNKMallinckrodt management to meet with Guggenheim
Subscribe for More Information
10:00 EDTPRGOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at BofA/Merrill... Angie's List (ANGI) initiated with a Hold at Topeka... Avenue Financial (AVNU) initiated with an Equal Weight at Stephens... CASI Pharmaceuticals (CASI) initiated with a Buy at H.C. Wainwright... Corindus (CVRS) initiated with a Buy at Stifel... Coupons.com (COUP) initiated with a Market Perform at William Blair... Five Below (FIVE) initiated with an Outperform at RBC Capital... Franklin Financial Network (FSB) initiated with an Equal Weight at Stephens... Galmed (GLMD) initiated with a Buy at H.C. Wainwright... Genesis Healthcare (GEN) initiated with a Neutral at Susquehanna... Groupon (GRPN) initiated with a Hold at Topeka... GrubHub (GRUB) initiated with a Buy at Topeka... Hercules Technology (HTGC) initiated with a Buy at Compass Point... Immersion (IMMR) initiated with a Buy at Craig-Hallum... Lipocine (LPCN) initiated with a Buy at Canaccord... NeoGenomics (NEO) initiated with a Buy at BTIG... Novadaq (NVDQ) initiated with a Neutral at BTIG... Perrigo (PRGO) initiated with an Outperform at BMO Capital... Signal Genetics (SGNL) initiated with a Buy at Chardan... Standard Motor Products (SMP) initiated with a Neutral at CL King... United Community Financial (UCFC) initiated with a Market Perform at Keefe Bruyette... WP Glimcher (WPG) initiated with a Neutral at Goldman... WhiteWave (WWAV) initiated with a Buy at Maxim... Yelp (YELP) initiated with a Buy at Topeka.
09:20 EDTVRXValeant and Progenics announces submission of NDA to FDA for RELISTOR
Valeant Pharmaceuticals International (VRX) and Progenics Pharmaceuticals (PGNX) announced that Valeant submitted a New Drug Application, or NDA, to the FDA for RELISTOR, or methylnaltrexone bromide, Tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
08:49 EDTTEVA, PRGO, MYLMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
07:25 EDTVRXPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
06:01 EDTMYL, PRGOPerrigo initiated with an Outperform at BMO Capital
BMO Capital analyst David Maris started Perrigo (PRGO) with an Outperform rating and $246 price target. Maris calls shares "significantly undervalued" on a fundamental basis and sees limited downside risk should Mylan (MYL) remove its unsolicited bid for the company.
June 21, 2015
19:53 EDTPRGO, TEVA, MYLMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use